{
Apellis Pharmaceuticals, Inc.

Companies

}
001122334455554433221100
001122334455554433221100
Symbol APLS
Name Apellis Pharmaceuticals, Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State MA
City Waltham
Zipcode 2451
Website http://www.apellis.com
Track all markets on TradingView

complement 3 glomerulopathy pipeline advancements and emerging therapies in 2024

Complement 3 Glomerulopathy (C3G) is a rare kidney disorder marked by abnormal C3 protein deposits in the glomeruli. Key companies like Q32 Bio, Novartis, and Kira Pharmaceuticals are developing therapies such as KP104 and zaltenibart, with ongoing clinical trials aimed at addressing this condition's unmet medical needs. Recent advancements include Kira's promising Phase 2 results for KP104 and Omeros Corporation's FDA designation for zaltenibart, targeting this progressive disease primarily affecting children and young adults.
Barchart.com
United States Dollar Novartis AG Apellis Pharmaceuticals, Inc. Omeros Corporation USA Gaurav Bora Show more
Healthcare, Market Report
16:58 14.01.2025

Apellis Pharmaceuticals Shares Rise 18.4 Percent After Mixed Earnings Report

Apellis Pharmaceuticals reported a wider-than-expected loss of 46 cents per share for Q3 2024, compared to a loss of $1.17 per share a year ago. Total revenues reached $196.8 million, driven by strong sales of Syfovre, which generated $152 million, up 101.8% year over year, despite missing estimates. Empaveli sales rose to $24.6 million, and licensing revenues increased by 81.3%, while general and administrative expenses decreased by 16.2%.
Yahoo Finance
United States Dollar SoBit USD Apellis Pharmaceuticals, Inc. USA
Healthcare, Market Report
17:30 05.12.2024

apellis pharmaceuticals reports wider than expected loss and revenue miss

Apellis Pharmaceuticals, Inc. reported a Q3 loss of $0.46 per share, missing estimates and showing a significant improvement from a loss of $1.17 per share a year ago. Revenues of $196.83 million also fell short of expectations, despite a year-over-year increase from $110.4 million. The company's stock has declined 52.3% this year, and it currently holds a Zacks Rank #3 (Hold), indicating expected performance in line with the market.
Yahoo Finance
Apellis Pharmaceuticals, Inc. USA
Finance & Economy, Market Report
14:20 05.11.2024

us stock market gains led by tesla and nvidia amid election uncertainty

The U.S. stock market saw significant gains, with the S&P 500 rising 1.1%, the Dow Jones up 0.8%, and the Nasdaq jumping 1.2%, driven by key players like Tesla and Nvidia. Notable movers included 8x8 Inc. soaring 23.92% after strong quarterly results, while Archer-Daniels-Midland fell 8.52% due to disappointing earnings. Other significant shifts included Cummins Inc. climbing 8.69% and Bioventus plummeting 18.71% after missing margin expectations.
Moneycontrol
Alkermes Inc. Apellis Pharmaceuticals, Inc. American International Group, Inc. 8x8, Inc. Archer-Daniels-Midland Company USA Show more
Finance & Economy, Market Report
13:34 05.11.2024

apellis pharmaceuticals set to report earnings with mixed expectations

Apellis Pharmaceuticals, Inc. (APLS) is anticipated to report a quarterly loss of $0.32 per share, reflecting a 72.7% year-over-year improvement, with revenues expected to reach $198.89 million, an 80.2% increase. The consensus EPS estimate has been revised 8.61% lower in the past month, indicating analysts' reassessment of the company's performance. The upcoming earnings report on November 5 will be crucial, as actual results compared to expectations could significantly impact the stock price.
@YahooFinance
Apellis Pharmaceuticals, Inc. USA
Finance & Economy, Market Report
15:01 29.10.2024
Trending
Subcategory
Startups & Entrepreneurship Industry Trends Corporate News Private Equity Deals Retail and Consumer Goods Supply Chain Management Global Trade Developments CEO Changes Government Economic Policies Corporate Social Responsibility Industry Mergers & Acquisitions Workplace Trends Energy Sector Developments Venture Capital Investments Fintech Startups Finance Mergers & Acquisitions AI Innovations Market Analysis and Predictions Intellectual Property Laws Central Bank Actions
Countries:
IND USA CHN SAU ARE SGP JPN QAT EGY MYS IDN GBR KOR BRA HKG VNM TWN DEU FRA IRL
Companies:
Apple Inc. NVIDIA Corporation Google Inc. Amazon.com, Inc. Tesla, Inc. Salesforce, Inc. Garuda Aerospace Ltd. Huawei Technologies CO. Ltd. Bharti Airtel Ltd. XPeng Inc. Microsoft Corporation Venturewave Capital NO.1 Ltd. Semler Scientific, Inc. TENCENT Wipro Ltd OpenAI ERC USD Orange S.A. IDBI Bank Limited Standard Chartered Bank LENOVO GROUP
Currencies:
United States Dollar Indian Rupee Chinese Yuan Euro Saudi Riyal Japanese Yen Malaysian Ringgit British Pound Sterling Mexican Peso Brazilian Real New Taiwan Dollar Bahraini Dinar Qatari Riyal Pakistani Rupee Kuwaiti Dinar Vietnamese Đồng South Korean Won Algerian Dinar
People:
Donald Trump Mark Zuckerberg Bisrat Degefa He Xiaopeng Abdel Fattah El-Sisi Anmol Singh Jaggi Puneet Singh Jaggi Sari Sabban David Watkins Simon Moon Anas Algahtani Matt Jones Ayman Hamdan Elon Musk Allen Law Xi Jinping Anwar Hussain Sultan Ibrahim ibni Sultan Iskandar Prashant Joshi Albinder Dhindsa

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.